5-[8-[4-(5-fluoro-3-pyridyl)phenyl]-5-oxo-7-thioxo-6,8-diazaspiro[3.4]octan-6-yl]-3-methyl-pyridine-2-carbonitrile | 1332389-82-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-[8-[4-(5-fluoro-3-pyridyl)phenyl]-5-oxo-7-thioxo-6,8-diazaspiro[3.4]octan-6-yl]-3-methyl-pyridine-2-carbonitrile
• 英文别名: 5-[5-[4-(5-Fluoropyridin-3-yl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile
• CAS: 1332389-82-8
• 化学式: C₂₄H₁₈FN₅OS
• 分子量: 443.504
• InChiKey: FKTRYDSUYGNYDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DES ANDROGÈNES THIOHYDANTOÏNE POUR LE TRAITEMENT DU CANCER
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018037342A1

  公开（公告）日：2018-03-01

  Disclosed are compounds, compositions and methods for treating and/ or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) Formula (I) wherein R1, G, R10, and R11 are defined herein.

  本发明涉及化合物、组合物和方法，用于治疗和/或改善与与去势抵抗性前列腺癌相关的AR突变受体相关的疾病、综合征、障碍或病况，包括哺乳动物和/或人类在内，需要对第一代或第二代AR拮抗剂表现出抵抗性的对象。该方法包括、由以下组成或基本组成：向需要治疗的对象投与治疗有效量的I式化合物，其中R1、G、R10和R11在此被定义。
• [EN] ANDROGEN RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DU RÉCEPTEUR DES ANDROGÈNES ET LEURS UTILISATIONS
  申请人：ARAGON PHARMACEUTICALS INC

  公开号：WO2011103202A2

  公开（公告）日：2011-08-25

  Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.

  本文介绍的是雄激素受体调节剂化合物。还描述了包括所述化合物的制药组合物和药物，以及使用这种雄激素受体调节剂，单独或与其他化合物结合使用，治疗与雄激素受体有关或依赖于雄激素受体的疾病或病症的方法。
• ANDROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Smith Nicholas D.

  公开号：US20130116258A1

  公开（公告）日：2013-05-09

  Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.

  本文描述了一些雄激素受体调节剂化合物。还描述了包括上述化合物的药物组合物和药物，以及使用这些雄激素受体调节剂，单独或与其他化合物组合使用，治疗与雄激素受体相关或依赖的疾病或病症的方法。
• Androgen receptor modulators and uses thereof
  申请人：Aragon Pharmaceuticals, Inc.

  公开号：EP2824102A1

  公开（公告）日：2015-01-14

  Described herein are compounds (Ia) that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors. The treatment of cancer is claimed.

  本文描述的化合物（Ia）是雄激素受体调节剂。还描述了包括本文所述化合物的药物组合物和药物，以及单独或与其他化合物结合使用这种雄激素受体调节剂治疗介导或依赖于雄激素受体的疾病或病症的方法。 要求治疗癌症。
• THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER
  申请人：Jaressen Pharmaceutica NV

  公开号：US20180008587A1

  公开（公告）日：2018-01-11

  Disclosed are compounds, compositions and methods for treating and/or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) wherein R 1 , G, R 10 , and R 11 are defined herein.